EP1315512A4 - Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden - Google Patents

Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden

Info

Publication number
EP1315512A4
EP1315512A4 EP01970682A EP01970682A EP1315512A4 EP 1315512 A4 EP1315512 A4 EP 1315512A4 EP 01970682 A EP01970682 A EP 01970682A EP 01970682 A EP01970682 A EP 01970682A EP 1315512 A4 EP1315512 A4 EP 1315512A4
Authority
EP
European Patent Office
Prior art keywords
disclosed
targeting
peptides
novel
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01970682A
Other languages
English (en)
French (fr)
Other versions
EP1315512A2 (de
Inventor
Wadih Arap
Renata Pasqualini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of EP1315512A2 publication Critical patent/EP1315512A2/de
Publication of EP1315512A4 publication Critical patent/EP1315512A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
EP01970682A 2000-09-08 2001-09-07 Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden Withdrawn EP1315512A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23126600P 2000-09-08 2000-09-08
US231266P 2000-09-08
US76510101A 2001-01-17 2001-01-17
US765101 2001-01-17
PCT/US2001/028045 WO2002020724A2 (en) 2000-09-08 2001-09-07 Adenoviral targeting and manipulation of immune system response using targeting peptides

Publications (2)

Publication Number Publication Date
EP1315512A2 EP1315512A2 (de) 2003-06-04
EP1315512A4 true EP1315512A4 (de) 2005-11-09

Family

ID=26924954

Family Applications (6)

Application Number Title Priority Date Filing Date
EP08016646A Withdrawn EP2028187A1 (de) 2000-09-08 2001-09-07 Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide
EP01970682A Withdrawn EP1315512A4 (de) 2000-09-08 2001-09-07 Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden
EP01970681A Withdrawn EP1315830A4 (de) 2000-09-08 2001-09-07 Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
EP01968603A Expired - Lifetime EP1322755B1 (de) 2000-09-08 2001-09-07 Durch phagendisplay identifizierte zielpeptide des menschen und der maus
EP01970671A Withdrawn EP1315965A4 (de) 2000-09-08 2001-09-07 Verfahren und zusammensetzungen für "targeting" in vitro
EP01968683A Withdrawn EP1315840A4 (de) 2000-09-08 2001-09-07 Biopanning und schnelle analyse von selektiven interaktiven liganden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08016646A Withdrawn EP2028187A1 (de) 2000-09-08 2001-09-07 Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP01970681A Withdrawn EP1315830A4 (de) 2000-09-08 2001-09-07 Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
EP01968603A Expired - Lifetime EP1322755B1 (de) 2000-09-08 2001-09-07 Durch phagendisplay identifizierte zielpeptide des menschen und der maus
EP01970671A Withdrawn EP1315965A4 (de) 2000-09-08 2001-09-07 Verfahren und zusammensetzungen für "targeting" in vitro
EP01968683A Withdrawn EP1315840A4 (de) 2000-09-08 2001-09-07 Biopanning und schnelle analyse von selektiven interaktiven liganden

Country Status (7)

Country Link
EP (6) EP2028187A1 (de)
JP (6) JP2004530404A (de)
AT (1) ATE478141T1 (de)
CA (5) CA2421195A1 (de)
DE (1) DE60142840D1 (de)
PT (1) PT1322755E (de)
WO (4) WO2002020722A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313779T3 (es) * 1998-03-13 2009-03-01 The Burnham Institute Moleculas que migran a diversos organos o tejidos seleccionados.
AU2001288914A1 (en) * 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2003070749A2 (en) 2002-02-15 2003-08-28 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1346729A1 (de) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Zielgerichtete Therapie der myokardialen Angiogenese durch CD13/APN
WO2003106640A2 (en) 2002-06-14 2003-12-24 Case Western Reserve University Cell targeting methods and compositions
CA2496938A1 (en) * 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
CN101791409A (zh) * 2003-04-22 2010-08-04 研究及应用科学协会股份有限公司 肽载体
US20040248109A1 (en) * 2003-06-09 2004-12-09 Lawrence Greenfield Methods for selecting protein binding moieties
US20050187161A1 (en) * 2003-09-12 2005-08-25 Board Of Regents, The University Of Texas System Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive Aspergillosis
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
JP2011239784A (ja) * 2003-12-04 2011-12-01 Perseus Proteomics Inc 細胞表面抗原に対する抗体取得とその抗原同定
US7544661B2 (en) * 2003-12-05 2009-06-09 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
US8377484B1 (en) * 2004-05-06 2013-02-19 Maria V. Tsiper Tumor encapsulation for prevention and treatment of metastatic cancer disease
CN1294418C (zh) * 2004-08-09 2007-01-10 中国人民解放军南京军区南京总医院 检测白念珠菌菌丝蛋白抗体的方法及试剂盒
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
ITRM20040568A1 (it) * 2004-11-18 2005-02-18 Uni Degli Studi Di Roma Tor Vergata Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi.
WO2006114478A1 (en) * 2005-04-26 2006-11-02 Karyon-Ctt Ltd Diagnostic and therapeutic agents
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5167155B2 (ja) * 2006-03-09 2013-03-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法
EP2130552B1 (de) 2007-02-27 2016-06-15 Chugai Seiyaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit einem anti-grp78-antikörper als wirkstoff
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US7807630B2 (en) * 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
MX2011010780A (es) 2009-04-13 2011-10-28 Univ Northwestern Andamios novedosos basados en peptido para la regeneracion de cartilagos y metodos para su uso.
HUE038787T2 (hu) 2011-02-11 2018-11-28 Univ Michigan Regents Tripeptid készítmények és alkalmazásuk diabétesz kezelésére
EP2812349B1 (de) * 2012-02-10 2021-09-01 Cambridge Enterprise Limited Verfahren zur charakterisierung von wechselwirkungsbereichen bei zielproteinen
WO2013149237A1 (en) * 2012-03-30 2013-10-03 Board Of Regents, The University Of Texas System Targeting intracellular organelle zip codes with functional homing ligands from cell-internalizing phage combinatorial libraries
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN103497236B (zh) * 2013-09-25 2017-05-10 浙江省医学科学院 靶向wisp‑1蛋白的特异性七肽及其应用
GB2522412A (en) * 2014-01-22 2015-07-29 Agency Science Tech & Res Antimicrobial peptidomimetics
SG11201606824VA (en) * 2014-02-19 2016-09-29 Hoffmann La Roche Blood brain barrier shuttle
US10799568B2 (en) * 2014-05-19 2020-10-13 Valo Therapeutics Oy Modified adenoviruses for cancer vaccines development
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105769909A (zh) * 2016-05-13 2016-07-20 云南舜喜再生医学工程有限公司 一种直接获得富含细胞因子血清的采血器及方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
EP3856224A4 (de) * 2018-09-25 2022-07-06 Emory University Nukleinsäuren zur erkennung und integration von zellen
CN109137086A (zh) * 2018-10-16 2019-01-04 梁耀极 一种改良的全长mRNA测序的建库方法
BR102019014302A2 (pt) 2019-07-10 2021-12-28 Universidade Federal de Uberlândia Peptídeos recombinantes ligantes ao anticorpo tumoral específico para cancer de mama e uso
EP3767628B1 (de) 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Selektion von antikörpern / antikörperfragmenten
JP7750490B2 (ja) * 2019-12-17 2025-10-07 国立大学法人三重大学 線維症の評価および処置のための方法および組成物
KR102749110B1 (ko) * 2021-11-04 2025-01-03 (주)케어젠 생리 활성을 갖는 펩타이드 및 그의 용도
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
WO2026048943A1 (ja) * 2024-08-30 2026-03-05 三井化学株式会社 がん標的ペプチド、輸送キャリア、及び、医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046284A2 (en) * 1998-03-13 1999-09-16 The Burnham Institute Molecules that home to various selected organs or tissues

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5206347A (en) 1985-08-06 1993-04-27 La Jolla Cancer Research Foundation Isolation and use of receptors binding to a peptide column
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
DK0525132T3 (da) 1991-02-14 1996-02-05 Baxter Int Binding af genkendende stoffer til liposomer
US5603872A (en) 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
AU684510B2 (en) * 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
JP3900305B2 (ja) * 1995-09-11 2007-04-04 ザ バーナム インスティテュート インビボにおいて選択された器官または組織に帰巣する分子および同分子を同定する方法
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
EP1109897A1 (de) * 1998-09-07 2001-06-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zur selektion von peptiden für zielgerichteten pharma- und markertransport und peptide damit entdeckt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046284A2 (en) * 1998-03-13 1999-09-16 The Burnham Institute Molecules that home to various selected organs or tissues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075 *
ELLERBY H M ET AL: "ANTI-CANCER ACTIVITY OF TARGETED PRO-APOPTOTIC PEPTIDES", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP000995556, ISSN: 1078-8956 *
RAJOTTE D ET AL: "MEMBRANE DIPEPTIDASE IS THE RECEPTOR FOR A LUNG-TARGETING PEPTIDE IDENTIFIED BY IN VIVO PHAGE DISPLAY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11593 - 11598, XP000869582, ISSN: 0021-9258 *
WANG H ET AL: "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 18 JAN 2000, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 847 - 852, XP001206541, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002020822A3 (en) 2002-06-27
WO2002020822A2 (en) 2002-03-14
CA2421195A1 (en) 2002-03-14
ATE478141T1 (de) 2010-09-15
EP1315840A4 (de) 2005-11-02
WO2002020724A3 (en) 2002-07-11
JP2012065662A (ja) 2012-04-05
WO2002020722A3 (en) 2003-02-06
WO2002020723A2 (en) 2002-03-14
PT1322755E (pt) 2010-11-19
JP2011120587A (ja) 2011-06-23
JP2004530404A (ja) 2004-10-07
DE60142840D1 (de) 2010-09-30
JP2004515751A (ja) 2004-05-27
WO2002020722A9 (en) 2003-08-21
CA2421200A1 (en) 2002-03-14
EP1315840A2 (de) 2003-06-04
WO2002020722A2 (en) 2002-03-14
JP5591209B2 (ja) 2014-09-17
EP1322755A1 (de) 2003-07-02
EP2028187A1 (de) 2009-02-25
WO2002020724A2 (en) 2002-03-14
EP1315512A2 (de) 2003-06-04
EP1322755B1 (de) 2010-08-18
CA2421271A1 (en) 2002-03-14
WO2002020723A3 (en) 2002-08-29
EP1315965A2 (de) 2003-06-04
JP2004533803A (ja) 2004-11-11
EP1315965A4 (de) 2006-04-05
EP1322755A4 (de) 2006-04-05
CA2421191A1 (en) 2002-03-14
JP2004536020A (ja) 2004-12-02
EP1315830A2 (de) 2003-06-04
CA2421380A1 (en) 2002-03-14
EP1315830A4 (de) 2005-10-19

Similar Documents

Publication Publication Date Title
EP1315512A4 (de) Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden
ES2629086T3 (es) Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
Bausero et al. Surface expression of Hsp25 and Hsp72 differentially regulates tumor growth and metastasis
DE69922933D1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
ES2107041T3 (es) Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
AP2004002986A0 (en) Use of biologically active HIV-1 TAT, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
ATE336267T1 (de) Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
DE60018920D1 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
DE19580890D2 (de) Lebendvakzine zur Behandlung von Tumorerkrankungen
EP1410804A4 (de) Krebsvakzine mit krebsantigen auf basis von tumor-suppressor-gen wt1 produkt und kationische liposome
WO1998039426A3 (en) Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
DE69434244D1 (de) Verbesserte krebstherapie
ATE423574T1 (de) Dominant-negativer plb mutant zur behandlung der herzerkrankungen
ES2439954T3 (es) Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
ATE364315T1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
WO2003092598A3 (en) Treatment for pompe disease
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
ATE371737T1 (de) Proteaseresistente flint-analoge
ATE239749T1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
HK1044568A1 (zh) 一种治疗剂的应激应答性诱导及其使用方法
MX9708615A (es) Terapia de genes animales.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030307

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PASQUALINI, RENATA

Inventor name: ARAP, WADIH

A4 Supplementary search report drawn up and despatched

Effective date: 20050923

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051217

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PASQUALINI, RENATA

Inventor name: ARAP, WADIH